Further characterization of agmatine binding to mitochondrial membranes: involvement of imidazoline I2 receptor.

Agmatine, a divalent diamine with two positive charges at physiological pH, is transported into the matrix of liver mitochondria by an energy-dependent mechanism, the driving force of which is the electrical membrane potential. Its binding to mitochondrial membranes is studied by applying a thermodynamic treatment of ligand-receptor interactions on the analyses of Scatchard and Hill. The presence of two mono-coordinated binding sites S(1) and S(2), with a negative influence of S(2) on S(1), has been demonstrated. The calculated binding energy is characteristic for weak interactions. S(1) exhibits a lower binding capacity and higher binding affinity both of about two orders of magnitude than S(2). Experiments with idazoxan, a ligand of the mitochondrial imidazoline receptor I(2), demonstrate that S(1) site is localized on this receptor while S(2) is localized on the transport system. S(1) would act as a sensor of exogenous agmatine concentration, thus modulating the transport of the amine by its binding to S(2)

Agmatidine, a modified cytidine in the anticodon of archaeal tRNA {superscript Ile], base pairs with adenosine but not with guanosine

Modification of the cytidine in the first anticodon position of the AUA decoding tRNAIle [tRNA superscript Ile subscript 2] of bacteria and archaea is essential for this tRNA to read the isoleucine codon AUA and to differentiate between AUA and the methionine codon AUG. To identify the modified cytidine in archaea, we have purified this tRNA species from Haloarcula marismortui, established its codon reading properties, used liquid chromatography–mass spectrometry (LC-MS) to map RNase A and T1 digestion products onto the tRNA, and used LC-MS/MS to sequence the oligonucleotides in RNase A digests. These analyses revealed that the modification of cytidine in the anticodon of [tRNA superscript Ile subscript 2] adds 112 mass units to its molecular mass and makes the glycosidic bond unusually labile during mass spectral analyses. Accurate mass LC-MS and LC-MS/MS analysis of total nucleoside digests of the [tRNA superscript Ile subscript 2] demonstrated the absence in the modified cytidine of the C2-oxo group and its replacement by agmatine (decarboxy-arginine) through a secondary amine linkage. We propose the name agmatidine, abbreviation C+, for this modified cytidine. Agmatidine is also present in Methanococcus maripaludis [tRNA superscript Ile subscript 2] and in Sulfolobus solfataricus total tRNA, indicating its probable occurrence in the AUA decoding tRNAIle [tRNA superscript Ile] of euryarchaea and crenarchaea. The identification of agmatidine shows that bacteria and archaea have developed very similar strategies for reading the isoleucine codon AUA while discriminating against the methionine codon AUG.National Institutes of Health (U.S.) (Grant GM17151) (Grant GM22854) (Grant RR19900)National Science Foundation (U.S.) (Grant CHE0602413) (Grant CHE0910751)United States. Dept. of Energy (Grant DE-FG36-08GO88055

Underwater Live Fish Recognition by Deep Learning

International audienc

Privação de sono REM em um modelo experimental da doença de Parkinson

Investigação prévia mostrou que ratos privados de sono (REM SD) mostram acentuação de resposta a agonistas dopaminérgicos. As evidências indicam que essa ação parece ser mediada por supersensibilização de receptores dopaminérgicos pós-sinápticos. Com base nisso, foi feita REM SD em ratos com modelo experimental da doença de Parkinson, nos quais foi feita lesão eletrolítica bilateral de ambas as vias nigro-estriatais. Sete dias após a cirurgia os animais eram submetidos a REM SD por 72 horas. Imediatamente após o final deste período era feita observação em campo aberto para a ambulação, "rearing", "grooming" e latência. Em comparação com ratos não-privados foi observado aumento significativo na ambulação e "rearing", resposta que reapareceu após um segundo período de REM SD, realizado 21 dias após a cirurgia. Estes dados, de melhora de dois parâmetros de modelo experimental da doença de Parkinson, sugerem que a privação de sono pode ser útil nesta doença